Melatonin Therapy in Patients with Alzheimer’s Disease

Daniel P. Cardinali 1,*, Daniel E. Vigo 1, Natividad Olivar 2, María F. Vidal 2 and Luis I. Brusco 2

1 Departamento de Docencia e Investigación, Facultad de Ciencias Médicas, Pontificia Universidad Católica Argentina, Buenos Aires 1007, Argentina; E-Mail: dvigo@conicet.gov.ar

2 Centro de Neuropsiquiatría y Neurología de la Conducta, Hospital de Clínicas “José de San Martín”, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires 1121, Argentina; E-Mails: natividad.olivar@gmail.com (N.O.); flovidal@hotmail.com (M.F.V.); brusco@neuropsiquiatria.org.ar (L.I.B.)

* Author to whom correspondence should be addressed; E-Mail: danielcardinali@uca.edu.ar or danielcardinali@fibertel.com.ar; Tel.: +54-11-4349-0200 (ext. 2310).

Received: 8 February 2014; in revised form: 9 March 2014 / Accepted: 17 March 2014 / Published: 10 April 2014

Abstract: Alzheimer’s disease (AD) is a major health problem and a growing recognition exists that efforts to prevent it must be undertaken by both governmental and non-governmental organizations. In this context, the pineal product, melatonin, has a promising significance because of its chronobiotic/cytoprotective properties potentially useful for a number of aspects of AD. One of the features of advancing age is the gradual decrease in circulating melatonin levels. A limited number of therapeutic trials have indicated that melatonin has a therapeutic value as a neuroprotective drug in the treatment of AD and minimal cognitive impairment (which may evolve to AD). Both in vitro and in vivo, melatonin prevented the neurodegeneration seen in experimental models of AD. For these effects to occur, doses of melatonin about two orders of magnitude higher than those required to affect sleep and circadian rhythmicity are needed. More recently, attention has been focused on the development of potent melatonin analogs with prolonged effects, which were employed in clinical trials in sleep-disturbed or depressed patients in doses considerably higher than those employed for melatonin. In view that the relative potencies of the analogs are higher than that of the natural compound, clinical trials employing melatonin in the range of 50–100 mg/day are urgently needed to assess its therapeutic validity in neurodegenerative disorders such as AD.
Keywords: melatonin; Alzheimer’s disease; neurodegeneration; free radicals; oxidative stress; aging; mild cognitive impairment; melatonin analogs

1. Introduction

Neurodegenerative disorders are a group of chronic and progressive diseases characterized by selective and symmetric losses of neurons in cognitive, motor, or sensory systems. Alzheimer’s disease (AD) is the most clinically relevant representative of this type of disorders. Although the origin of the specific neurodegeneration in AD remains undefined, three major and frequently interrelated processes, namely free radical-mediated damage, mitochondrial dysfunction, and excitotoxicity, underlie the pathophysiological mechanisms leading to neuronal death [1].

AD has a very large impact on health. In a recent publication [2] the Alzheimer’s Disease International (ADI) organization states that 44 million people live with dementia today and that this figure will rise to 135 million people by 2050. The current economic cost of dementia is $604 billion annually. It must be noted that the new estimates are an increase of 17% on the figures published in 2009, population aging being the main driver of the projected increase. The ADI report also predicts a shift in the distribution of the global burden of dementia by 2050, with 71% of all affected people living in low- or middle-income countries. It is estimated that 10% of dementia cases may be avoided by campaigns that target obesity, hypertension, diabetes, underactivity, and smoking, as well as by education and cognitive enhancement. Thus, a growing recognition exists that efforts to prevent AD at an early stage of development must be urgently undertaken.

The regular intake of antioxidants by the elderly has been one of the strategies recommended for prevention of age-associated, free radical-mediated, neurodegenerative diseases, but the efficacy of this treatment is debated [3]. In this context, the use of melatonin as a cytoprotective agent becomes of great interest. Melatonin is a well-conserved methoxyindole found in most phyla and having remarkable cytoprotective actions in addition to chronobiotic properties. The source of circulating melatonin is the pineal gland, and a substantial amount of data support that plasma melatonin decrease is one of the features of advancing age [4]. We will briefly review some relevant aspects of melatonin’s biology as far as the neurodegenerative process is concerned. Then, the theory and mode of action of melatonin in AD will be discussed. Finally, the clinical studies supporting the therapeutic use of melatonin in AD will be critically assessed.

2. Basic Biology of Melatonin Relevant to Neurodegeneration

Circulating melatonin in mammals derives almost exclusively from the pineal gland [5]. In addition, melatonin is locally synthesized in many cells, tissues, and organs, including lymphocytes, bone marrow, the thymus, the gastrointestinal tract, skin, and the eyes (see [6,7]). The fact that the occurrence of melatonin is not restricted to vertebrates, but rather is almost ubiquitously present in numerous taxa including, e.g., bacteria, unicellular eukaryotes, and plants [6,8], underlines that this molecule has gained many additional functions in the course of evolution.
Both in other animals and in humans, melatonin participates in diverse physiological functions signaling not only the length of the night but also facilitating, among other, free radical scavenging and the immune response, thus, showing relevant cytoprotective properties [6]. Indeed, cytoprotection may well explain melatonin’s presence in most living organisms. The systemic and intracellular functions of melatonin differ in the amounts of agonist needed. Generally melatonin effects on biologic rhythms are exerted at nanomolar concentrations and via receptor-mediated mechanisms. The cytoprotective effects of melatonin needs 100–1000 higher concentrations, compatible with the amounts reached intracellularly by melatonin in several tissues [7].

Circulating melatonin binds to albumin [9] and is metabolized mainly in the liver primarily through hydroxylation at the C6 position. This is catalyzed selectively by the hepatic microsomal cytochrome P450 1A2 (CYP1A2), with minor contributions from hepatic CYP2C19 and the largely extrahepatic CYP1A1 and CYP1B11A [9–12]. The formed 6-hydroxymelatonin is then conjugated with sulphate or glucuronide to be excreted in the urine. Another important metabolite is N-acetylserotonin which is formed by O-demethylation, and may represent as much as 20% of a melatonin administered dose [13].

Melatonin is also metabolized in tissues by oxidative pyrrole ring cleavage into kynuramine derivatives. The primary cleavage product is $N^{\text{1}}$-acetyl-$N^{\text{2}}$-formyl-5-methoxykynuramine (AFMK), which is deformylated, either by aryamine formamidase or by hemoperoxidase, to $N^{\text{1}}$-acetyl-5-methoxykynuramine (AMK) [14]. It has been proposed that AFMK is the primary active metabolite of melatonin to mediate cytoprotection [15]. Melatonin is also converted into cyclic 3-hydroxymelatonin in a process that directly scavenges two hydroxyl radicals [15]. Due to its rapid metabolism, melatonin has a short half-life of approximately one hour, although there is a marked inter-individual variation in plasma levels of melatonin after oral administration [16–18].

The two membrane melatonin receptors cloned so far (MT$_1$ and MT$_2$) have seven membrane domains and belong to the superfamily of G-protein coupled receptors [19]. MT$_1$ and MT$_2$ receptors are found in the cell membrane as dimers and heterodimers. GPR50, a G-protein coupled melatonin receptor ortholog that does not bind melatonin itself, dimerizes with MT$_1$ receptors and can block melatonin binding [20]. The human MT$_2$ receptor exhibits a lower affinity than the human MT$_1$ receptor and becomes desensitized after exposure to melatonin, presumably by internalization.

As representatives of the G-protein coupled receptor family, MT$_1$ and MT$_2$ receptors act through a number of signal transduction mechanisms [19]. The MT$_1$ receptor is coupled to G proteins that mediate adenylyl cyclase inhibition and phospholipase C activation. The MT$_2$ receptor is also coupled to the inhibition of adenylyl cyclase, and it additionally inhibits the soluble guanylyl cyclase pathway.

By using receptor autoradiography with the nonselective 2-[$^{125}$I]iodomelatonin ligand and real-time quantitative reverse transcription–polymerase chain reaction to label melatonin receptor mRNA, MT$_1$ and MT$_2$ receptors has been identified brain regions. At the level of the hippocampus, MT$_2$ receptors were detected in CA3 and CA4 pyramidal neurons, which receive glutamatergic excitatory inputs from the entorhinal cortex, whereas MT$_1$ receptors were predominantly expressed in CA1 [6].

Melatonin also binds to transcription factors belonging to the retinoic acid receptor superfamily, in particular, splice variants of ROR$\alpha$ (ROR$\alpha$1, ROR$\alpha$2, and ROR$\alpha$ isoform d) and RZR$\beta$ [21,22]. Retinoic acid receptor subforms are ubiquitously expressed in mammalian tissues [22].

Melatonin is a powerful antioxidant that scavenges ·OH radicals as well as other radical oxygen species (ROS) and radical nitrogen species (RNS), and that gives rise to the cascade of metabolites...
mentioned above that share antioxidant properties [23]. Melatonin also acts indirectly to promote gene expression of antioxidant enzymes and to inhibit gene expression of prooxidant enzymes [24–27]. In particular, this holds for glutathione peroxidase (GPx) and for glutathione reductase (GRd), presumably in response to GPx-dependent increases in GSSG, the oxidized form of glutathione (GSH). Melatonin contributes to maintain normal brain GSH levels [28] by stimulating GSH biosynthesis via \( \gamma \)-glutamyleysteine synthase and glucose-6-phosphate dehydrogenase [26,29]. Melatonin has a demonstrated superiority to vitamin C and E in protection against oxidative damage and in scavenging free radicals [23].

Melatonin has significant anti-inflammatory properties presumably by inhibiting nuclear factor \( \kappa B \) (NF\( \kappa B \)) binding to DNA, thus, decreasing the synthesis of proinflammatory cytokines through inhibition of cyclooxygenase (Cox) [30], mainly Cox-2 [31], and by suppression of inducible nitric oxide (NO) synthase (iNOS) gene expression [32]. Melatonin was shown to protect from oxidative stress at physiological concentrations [23,33]. Although melatonin’s direct action as an antioxidant agent is mostly independent of receptor interaction [34], the upregulation of antioxidant enzymes by the methoxyindole involves nuclear transcription and in some cases RZR/ROR\( \alpha \) receptors [35].

The efficacy of melatonin in inhibiting oxidative damage has been tested in a variety of neurological disease models. In addition to the animals models of AD discussed below, melatonin has been shown to lower neural damage due to cadmium toxicity [36,37], hyperbaric hyperoxia [38,39], \( \delta \)-aminolevulinic acid toxicity [40–42], \( \gamma \) radiation [43–45], focal ischemia [46,47], brain trauma [48–50], and a number of neurotoxins [51].

Melatonin’s neuroprotective properties, as well as its regulatory effects on circadian disturbances, validate its benefits as a therapeutic substance in the preventive treatment of AD. Moreover, melatonin exerts anti-excitatory, and at sufficient dosages, sedating effects [52,53], thus that a second neuroprotective mode of action may exist involving the \( \gamma \)-aminobutyric acid (GABA)-ergic system as a mediator. This view is supported by studies indicating that melatonin protects neurons from the toxicity of the amyloid-\( \beta \) (A\( \beta \)) peptide (a main neurotoxin involved in AD) via activation of GABA receptors [54].

Early studies on the anti-excitotoxic actions of melatonin employed kainate, an agonist of ionotropic glutamate receptors, and gave support to the hypothesis that melatonin prevents neuronal death induced by excitatory amino acids [55,56]. It has also been reported that administration of melatonin reduces the injury of hippocampal CA1 neurons caused by transient forebrain ischemia [57,58] or high glucocorticoid doses [59].

The various types of toxicities listed above can result in neuronal death by necrosis or apoptosis. Apoptotic neuronal death requires RNA and protein synthesis and depletion of trophic factors. Apoptosis also involves single-strand breaks of DNA and neurotrophic factors have been found to rescue neurons from this type of death [60]. They may act via cellular anti-apoptotic components, such as the B cell lymphoma proto-oncogene protein (Bcl-2). In vitro studies indicate that melatonin enhances expression of Bcl-2 and prevents apoptosis [61–63]. In addition, melatonin directly inhibits the opening of the mtPTP, thereby rescuing cells [64–66].

The aging process of the brain is presently known in sufficient detail [67]. A number of senescence processes rely on mitochondrial damage including apoptosis via cardiolipin peroxidation, cytochrome C release and mtPTP breakdown and reduction of the mitochondrial mass. The blockade
of the electron transport chain leads to insufficient energy supply and impaired cell function and viability. The augmented ROS and RNS generation cause concomitant damage to endothelia, DNA proteins, and lipids. In addition neuronal overexcitation with calcium overload and activation of microglia occur with age. As a consequence of DNA damage, an increased telomere attrition takes place together with a reduction in cells with high proliferative capacity like immune progenitor cells thus leading to immunosenescence [67]. This situation is accompanied by the augmentation of autoimmune responses and by an inflammatory process leading to the increase of proinflammatory cytokines.

Evidence derived from animal studies indicates that melatonin may curtail most aspects of brain aging [67]. First, via action on central and peripheral circadian oscillators melatonin increases the depressed rhythm amplitudes and poor coordination of rhythms seen in the aged individuals. Melatonin affects clock protein expression and may modulate the disrupted metabolic sensing in senescence. Through the support of mitochondrial electron flux and reduction of electron overflow melatonin improves respiratory efficiency and energy supply and prevents apoptosis. The reduction of ROS and RNS exerted via radical scavenging, upregulation of antioxidant enzymes, inhibition of prooxidant enzymes, increase of GSH, and lower radical formation brings about a reduced damage to proteins, lipids, and DNA, together with inhibition of oxidant-induced telomere attrition and neuronal overexcitation. The antinflammatory actions of melatonin are crucial in reducing aging-related processes, as well as the improved insulin sensitivity and counteraction of the metabolic syndrome attributed to the methoxyindole. Lastly, melatonin modulates natural and adaptive immunity and improves immunosenescence, in part via a greater number of cells with high proliferative capacity, including leukocytes, stem, and progenitor cells [67].

3. Overview of Melatonin Therapy for Alzheimer’s Disease—Theory and Mode of Action

Extracellular senile plaques, formed mainly by Aβ deposits, and intracellular neurofibrillary tangles, resulting mainly from abnormally hyperphosphorylated microtubule-associated protein (MAP) tau are the major pathological characteristic of AD. Aβ plays an important role in promoting neuronal degeneration in AD turning neurons vulnerable to age-related increases in the levels of oxidative stress and an altered cellular energy metabolism.

Aβ is composed by 39–43 amino acid residues derived from its precursor, the amyloid precursor protein (APP) [68]. APP is proteolytically processed by α- or β-secretases in different pathways. The α-non-amyloidogenic pathway involves cleavage of APP by α-secretase to release an N-terminal fragment of APP, which after cleavage by γ-secretase precludes the formation of the Aβ [68]. The β-amyloidogenic pathway includes β-secretase, which results in the formation of intact Aβ peptide and is mediated by the sequential cleavage of β-secretase and γ-secretase at the N- and C-terminal of Aβ sequence [68].

Melatonin inhibited the normal levels of soluble APP secretion in different cell lines interfering with APP maturation [69]. Additionally, the administration of melatonin efficiently reduces Aβ generation and deposition in vivo [70,71] and in vitro [69,72–74]. Generally, the results in transgenic mice support the view that melatonin should be given at an early phase to regulates APP and Aβ metabolism mainly by preventing their formation, with little anti-amyloid effect later on. Thus, melatonin therapy in old Tg2576 mice starting at 14 months of age could not prevent additional Aβ
deposition [75] while a similar treatment starting at the fourth month of age was effective to reduce it [70]. As amyloid plaque pathology typically is seen in 10- to 12-month-old Tg2576 mice [76] the data point out to the effectiveness of melatonin in preventing early amyloid plaque formation rather than afterwards.

How melatonin exerts its inhibitory effect on the generation of Aβ remains undefined. The proteolytic cleavage of APP by α-secretase pathway is regulated by many physiological and pathological stimuli particularly through protein kinase (PK) C activation and secretase-mediated cleavage of APP. The inhibition of glycogen synthase kinase-3 (GSK-3) and upregulation of c-Jun N-terminal kinase result in high activity of matrix metalloproteinases with increasing degradation of Aβ [77]. The activity of insulin-degrading enzyme (IDE) that regulates the levels of insulin, Aβ and APP, decreased after Aβ increase [78]. GSK-3 interacts with presenilin-1, a cofactor of γ-secretase, the phosphorylation of GSK-3 by PKC leading to γ-secretase inactivation. Indeed, GSK-3 can be one of the common signaling pathways, increasing Aβ generation and tau hyperphosphorylation, and melatonin could regulate APP processing through PKC and GSK-3 pathways (Figure 1).

Melatonin interacts with Aβ40 and Aβ42 and inhibits progressive β-sheet and/or amyloid fibrils [79,80]. This interaction between melatonin and Aβ appears to depend on structural melatonin characteristics rather than on its antioxidant properties, as it could not be mimicked by other free radical scavengers [79]. By blocking the formation of secondary sheets, melatonin not only reduces neurotoxicity but also facilitates peptide clearance increasing proteolytic degradation, e.g., by IDE.

**Figure 1.** Effect of melatonin on impaired brain insulin signaling in AD. The figure schematizes the processes linking impaired insulin/insulin receptor with senile plaques and neurofibrillary tangles. In parentheses, the demonstrated action of melatonin as discussed in the text.
Oxidative stress plays a central role in Aβ-induced neurotoxicity and cell death. Accumulating data support that melatonin effectively protects cells against Aβ-induced oxidative damage and cell death in vitro [81,82] and in vivo [70,81,83–85]. In cells and animals treated with Aβ, melatonin could exert its protective activity through an antioxidant effect, whereas in APP transfected cells and transgenic animal models, the underlying mechanism may involve primarily the inhibition of generation of β-sheets and/or amyloid fibrils. Aggregated Aβ generates ROS that produce neuronal death through damage of neuronal membrane lipids, proteins and nucleic acids. Protection from Aβ toxicity by melatonin was observed, especially at the mitochondrial level [86,87].

The hyperphosphorylation of tau reduces tau capacity to prevent microtubule changes and the disruption of the cytoskeleton ensues [88,89]. The extent of neurofibrillary pathology correlates with the severity of dementia in AD patients. The level of hyperphosphorylated tau is three to four times higher in the brain of AD patients than in normal adult brains [90,91]. Melatonin efficiently attenuates tau hyperphosphorylation by affecting protein kinases and phosphatases in a number of experimental models including exposure of N2a and SH-SY5Y neuroblastoma cells to wortmannin [92], calyculin A [93–95], and okadaic acid [96–99]. Melatonin also antagonizes the oxidative stress given by these agents [100,101]. The inhibition of melatonin biosynthesis in rats not only resulted in impairment of spatial memory, but also induced an increase in tau phosphorylation, an effect prevented by melatonin supplementation [102].

Oxidative stress is known to influence tau phosphorylation state [103,104]. The accumulation of misfolded and aggregated proteins in brain neurons of AD is considered a consequence of oxidative stress, in addition to the molecular structural changes due to age [105]. As melatonin prevents, as an antioxidant and free radical scavenger, overproduction of free radicals, it seems feasible that the prevention of tau phosphorylation by melatonin is partly occurring due to its antioxidant activity. In addition several studies indicated melatonin may act as a modulator of enzymes in a way that is unrelated to its antioxidant properties. These include the regulation by melatonin of PKA [100,101], PKC [106,107], Ca²⁺/calmodulin-dependent kinase II [108–110] and mitogen-activated protein kinase [111].

An important factor in the pathogenesis of AD is the activation of microglia resulting in a higher level of expression of proinflammatory cytokines [112–115]. Epidemiological studies have shown that the use of anti-inflammatory drugs decreases the incidence of AD [116]. Aβ-induced microglial activation is a major source of inflammatory response [117]. Melatonin attenuated the production of proinflammatory cytokines induced by Aβ, NFκB, and NO in the rat brain [85,118]. Moreover, the DNA binding activity of NFκB was inhibited by melatonin [119,120].

Another major event in the pathogenesis of AD is the deficit in cholinergic function [121]. Neurons in the nucleus basalis of Meynert, the main source of cholinergic innervation to the cerebral cortex and the hippocampus, undergo a profound and selective degeneration in AD brains [122]. The levels of acetylcholine (ACh) are reduced at the early stage of AD whereas the activities of the synthesizing and degrading enzymes choline acetyltransferase (ChAT) and acetylcholinesterase (AChE) do not change until a late phase of AD [123,124]. As the decrease in ChAT activity in the neocortex of AD patients correlated with the severity of dementia, AChE inhibitors have become a standard treatment of mild to moderate AD [125].
Melatonin has a protective effect on the cholinergic system. It prevents the peroxynitrite-induced inhibition of choline transport and ChAT activity in synaptosomes and synaptic vesicles [126]. Melatonin treatment of eight-month-old APP695 transgenic mice significantly improved the profound reduction in ChAT activity in the frontal cortex and the hippocampus [81]. Melatonin also antagonizes the spatial memory deficit and the decreased ChAT activity found in adult ovariectomized rats [127]. However, in rats perfused intracerebroventricularly with Aβ for 14 days, melatonin was unable to restore ChAT activity [128]. Melatonin inhibited lipopolysaccharide- and streptozotocin-induced increase in AChE activity [129]. Recently hybrids of the AChE inhibitor tacrine and melatonin were synthesized as new drug candidates for treating AD [130,131]. These hybrids showed better antioxidant and cholinergic-preserving activity than tacrine or melatonin alone. The direct intracerebral administration of one of these hybrids decreased induced cell death and Aβ load in the APP/PS1 mouse brain parenchyma accompanied by a recovery of cognitive function [131].

There is a growing interest in the role of impaired brain insulin signaling in AD pathology. The disturbance of brain insulin/insulin-like growth factor 1 (IGF-1) signaling has been suggested to be a key causative event underlying AD, being linked to the presence of both senile plaques and neurofibrillary tangles [132–134]. This view, however, is not universally held [135]. An impaired insulin/insulin receptor (IR) signaling leads to decreased insulin-mediated activation of phosphoinositol 3-kinase (PI-3K)/Akt signaling activity, resulting in overactivation of GSK-3 which directly promotes tau hyperphosphorylation and Aβ accumulation and senile plaques formation (Figure 1). The activity of IDE, that regulates the levels of insulin, Aβ and APP, decreased after Aβ deposition [78]. The administration of melatonin reportedly reduces the signs of metabolic syndrome, such as hyperglycemia, dyslipidemia, hyperinsulinemia, insulin resistance, weight gain, and hypertension [136,137]. Melatonin restores insulin/insulin receptor mechanisms and increases phosphoinositide 3-kinase/Akt signaling activity with a resultant inhibition of GSK-3 and less Aβ accumulation and tau hyperphosphorylation (see [6]). Additionally, disruption of insulin signaling leads to a decreased glucose transporter-1 (GLUT-1) and -3 (GLUT-3) expression, culminating in impaired cerebral glucose uptake/metabolism, another event counteracted by melatonin. The restored neuronal glucose metabolism augments tau N-acetylglucosamine acylation, thus reducing tau hyperphosphorylation (Figure 1).

Figure 2 summarizes the major possible targets for medication in AD. The Food and Drug Administration (FDA) has only approved AChE inhibitors and N-methyl-D-aspartate (NMDA) receptor blockers for clinical use. As discussed above, melatonin has the unique property to affect all the physiopathological mechanisms depicted in Figure 2. Hence, its potential as a neuroprotector in AD deserves to be explored.
4. Clinical Aspects of Melatonin Application in AD

In demented patients the severity of mental impairment correlated significantly with impaired nocturnal melatonin production [138]. This may be an early sign of the disease since cerebrospinal fluid (CSF) melatonin levels are reduced in AD patients autopsied at the preclinical stage Braak stage-1. Hence the reduction in CSF melatonin may be a marker for the early detection of AD [139]. Additionally plasma melatonin levels are lower in AD patients [140–143] and functionally impaired retinal-SCN-pineal connections were postulated as cause for this decrease [144]. Expression and activity of monoamine oxidase gene augmented, and β1-adrenoceptor mRNA levels decreased, in the pineal gland of AD patients [145]. In addition changes in melatonin receptor immunoreactivity occurred in the AD hippocampus [146,147]. Collectively the results indicate that replacement of melatonin levels can be a therapeutic strategy for arresting AD progression.

“Sundowning”, a chronobiological phenomenon that includes disorganized thinking, reduced ability to maintain attention to external stimuli, wandering, agitation, and perceptual and emotional disturbances, is a situation commonly observed in AD patients. As a time-of-day related phenomenon, appearing in late afternoon or early evening [148,149], the possible therapeutic effect of melatonin was entertained. Table 1 summarizes the data indicating that melatonin, as a chronobiotic agent, may be effective in treating sundowning and irregular sleep-wake cycles in AD patients.
A review of the published results concerning melatonin use in AD [150] yielded eight reports (five open-label studies, two case reports) \((N = 89 \text{ patients})\) supporting a possible efficacy of melatonin: sleep quality improved and in patients with AD sundowning was reduced and cognitive decay slowed progression. In six double blind, randomized placebo-controlled trials, a total number of 210 AD patients were examined. Sleep quality increased and sundowning decreased significantly and cognitive performance improved in four studies \((N = 143)\) whereas there was absence of effects in two studies \((N = 67)\) [150].

Another systematic search of studies published between 1985 and April 2009 on melatonin and sundowning in AD patients was published [151]. All papers on melatonin treatment in dementia were retrieved and the effects of melatonin on circadian rhythm disturbances were scored by means of scoring sundowning/agitated behavior, sleep quality, and daytime functioning. A total of 9 papers, including 4 randomized controlled trials \((N = 243)\), and 5 case series \((N = 87)\) were reviewed (Table 1). Two of the randomized controlled trials found a significant improvement in sundowning/agitated behavior. All five case series found an improvement [151]. Thus, whether melatonin has any value in treating AD remains uncertain. Probably, the heterogeneity of the group examined in fully developed AD makes it difficult to disclose any therapeutic effect in studies including a small number of patients [152]. Moreover, the reduced hippocampal expression of MT\(_2\) melatonin receptors in AD patients [146] and of MT\(_1\) receptors in the circadian apparatus may explain why melatonin treatment is erratic at this advanced stage of the disease [153,154].
Table 1. Studies including treatment of Alzheimer’s disease (AD) patients with melatonin.

<table>
<thead>
<tr>
<th>Design</th>
<th>Subjects</th>
<th>Treatment</th>
<th>Time</th>
<th>Measured</th>
<th>Results</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Open-label study</td>
<td>10 AD patients</td>
<td>3 mg melatonin p.o./daily at bed time</td>
<td>3 weeks</td>
<td>Daily logs of sleep and wake quality completed by caretakers</td>
<td>7 out of 10 dementia patients having sleep disorders treated with melatonin showed a significant decrease in sundowning and reduced variability of sleep onset time</td>
<td>[155]</td>
</tr>
<tr>
<td>Open-label study</td>
<td>14 AD patients</td>
<td>9 mg melatonin p.o./daily at bed time</td>
<td>22 to 35 months</td>
<td>Daily logs of sleep and wake quality completed by caretakers. Neuro-psychological assessment</td>
<td>Sundowning was no longer detectable in 12 patients and persisted, although attenuated in 2 patients. A significant improvement of sleep quality was found. Lack of progression of the cognitive and behavioral signs of the disease during the time they received melatonin</td>
<td>[156]</td>
</tr>
<tr>
<td>Case report</td>
<td>Mono-zygotic twins with AD of 8 years duration</td>
<td>One of the patients was treated with melatonin 9 mg p.o./daily at bed time.</td>
<td>36 months</td>
<td>Neuro-psychological assessment. Neuroimaging</td>
<td>Sleep and cognitive function severely impaired in the twin not receiving melatonin as compared to the melatonin-treated twin</td>
<td>[157]</td>
</tr>
<tr>
<td>Open-label study</td>
<td>11 AD patients</td>
<td>3 mg melatonin p.o./daily at bed time</td>
<td>3 weeks</td>
<td>Daily logs of sleep and wake quality</td>
<td>Significant decrease in agitated behaviors in all three shifts; significant decrease in daytime sleepiness</td>
<td>[158]</td>
</tr>
<tr>
<td>Open-label, placebo-controlled trial</td>
<td>14 AD patients</td>
<td>6 mg melatonin p.o./daily at bed time or placebo</td>
<td>4 weeks</td>
<td>Daily logs of sleep and wake quality completed by caretakers. Actigraphy</td>
<td>AD patients receiving melatonin showed a significantly reduced percentage of nighttime activity compared to a placebo group</td>
<td>[159]</td>
</tr>
<tr>
<td>Randomized double blind placebo-controlled cross over study</td>
<td>25 AD patients</td>
<td>6 mg of slow release melatonin p.o. or placebo at bed time</td>
<td>7 weeks</td>
<td>Actigraphy</td>
<td>Melatonin had no effect on median total time asleep, number of awakenings or sleep efficiency</td>
<td>[160]</td>
</tr>
<tr>
<td>Open-label study</td>
<td>45 AD patients</td>
<td>6–9 mg melatonin p.o./daily at bed time</td>
<td>4 months</td>
<td>Daily logs of sleep and wake quality completed by caretakers. Neuro-psychological assessment</td>
<td>Melatonin improved sleep and suppressed sundowning, an effect seen regardless of the concomitant medication employed</td>
<td>[161]</td>
</tr>
</tbody>
</table>
Table 1. Cont.

<table>
<thead>
<tr>
<th>Study Design</th>
<th>Participants</th>
<th>Treatment</th>
<th>Duration</th>
<th>Assessments</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Randomized placebo-controlled trial</td>
<td>157 AD</td>
<td>2.5-mg slow-release melatonin, or 10-mg melatonin or placebo at bed time</td>
<td>2 months</td>
<td>Actigraphy. Caregiver ratings of sleep quality</td>
<td>Non significant trends for increased nocturnal total sleep time and decreased wake after sleep onset in the melatonin groups. Caregiver ratings of sleep quality showed a significant improvement in the 2.5-mg sustained-release melatonin group relative to placebo [162]</td>
</tr>
<tr>
<td>Double-blind, placebo-controlled study</td>
<td>20 AD</td>
<td>Placebo or 3 mg melatonin p.o./daily at bed time</td>
<td>4 weeks</td>
<td>Actigraphy. Neuro-psychological assessment</td>
<td>Melatonin significantly prolonged the sleep time and decreased activity in the night. Cognitive function was improved by melatonin [163]</td>
</tr>
<tr>
<td>Open-label study</td>
<td>7 AD</td>
<td>3 mg melatonin p.o./daily at bed time</td>
<td>3 weeks</td>
<td>Actigraphy. Neuro-psychological assessment</td>
<td>Complete remission of day-night rhythm disturbances or sundowning was seen in 4 patients, with partial remission in other 2 [164]</td>
</tr>
<tr>
<td>Randomized placebo-controlled study</td>
<td>17 AD</td>
<td>3 mg melatonin p.o./daily at bed time (7 patients). Placebo (10 patients)</td>
<td>2 weeks</td>
<td>Actigraphy. Neuro-psychological assessment</td>
<td>In melatonin-treated group, actigraphic nocturnal activity and agitation showed significant reductions compared to baseline [165]</td>
</tr>
<tr>
<td>Case report</td>
<td>68-year-old man with AD who developed rapid eye movement (REM) sleep behavior disorder</td>
<td>5–10 mg melatonin p.o./daily at bed time.</td>
<td>20 months</td>
<td>Polysomno-graphy</td>
<td>Melatonin was effective to suppress REM sleep behavior disorder [166]</td>
</tr>
<tr>
<td>Randomized placebo-controlled study</td>
<td>50 AD</td>
<td>Morning light exposure (2500 lux, 1 h) and 5 mg melatonin (N = 16) or placebo (N = 17) in the evening</td>
<td>10 weeks</td>
<td>Actigraphy</td>
<td>Light treatment alone did not improve nighttime sleep, daytime wake, or rest-activity rhythm. Light treatment plus melatonin increased daytime wake time and activity levels and strengthened the rest-activity rhythm [167]</td>
</tr>
<tr>
<td>Randomized placebo-controlled study</td>
<td>41 AD</td>
<td>Melatonin (8.5 mg immediate release and 1.5 mg sustained release) (N = 24) or placebo (N = 17) administered at 22:00 h</td>
<td>10 days</td>
<td>Actigraphy</td>
<td>There were no significant effects of melatonin, compared with placebo, on sleep, circadian rhythms, or agitation [168]</td>
</tr>
</tbody>
</table>

p.o.: per os.
Mild cognitive impairment (MCI) is the name given to signs and symptoms diagnosed in those who have an objective and measurable deficit in cognitive functions, but with a relative preservation of daily activities. Annual conversion rates to AD are as high as 10%–15% [169] and MCI represents a clinically important stage for identifying and treating individuals at risk. Indeed, the degenerative process in AD brain starts 20–30 years before the clinical onset of AD [170,171]. During this phase, the loads of plaques and tangles increase and at a certain threshold the first symptoms appear [172,173]. As mentioned above, CSF melatonin levels decrease in preclinical stages of AD, suggesting that the reduction of CSF melatonin may be an early trigger and marker for AD [139,145]. Although it is not known whether the relative melatonin deficiency is either a consequence or a cause of neurodegeneration, the loss in melatonin presumably aggraves the disease.

We previously reported a retrospective analysis in which daily 3–9 mg of a fast-release melatonin preparation *per os* (p.o.) at bedtime for up to three years significantly improved cognitive and emotional performance and daily sleep/wake cycle in 25 MCI patients [174]. Recently we reported data from another series of 96 MCI outpatients, 61 of who had received daily 3–24 mg of a fast-release melatonin preparation p.o. at bedtime for 15 to 60 months in comparison to a similar group of 35 MCI patients who did not receive it [175]. In addition, all patients received the individual standard medication considered appropriate by the attending psychiatrist.

Patients treated with melatonin exhibited significantly better performance in Mini–Mental State Examination and the cognitive subscale of the AD Assessment Scale. After application of a neuropsychological battery comprising a Mattis’ test, Digit-symbol test, Trail A and B tasks and the Rey’s verbal test, better performance was found in melatonin-treated patients for every parameter tested [175]. Abnormally high Beck Depression Inventory scores decreased in melatonin-treated patients, concomitantly with the improvement in the quality of sleep and wakefulness [175]. These results further support that melatonin is a useful add-on drug for treating MCI in a clinical environment.

Thus, an early initiation of melatonin treatment can be decisive for therapeutic success [75]. In Table 2, published data concerning melatonin treatment in MCI are summarized. Six double blind, randomized placebo-controlled trials and two open-label retrospective studies (*N* = 782) consistently showed that the administration of daily evening melatonin improves sleep quality and cognitive performance in MCI patients. Therefore, melatonin treatment could be effective at early stages of the neurodegenerative disease.

There are two reasons why it is beneficial to use melatonin in MCI patients. In the course of the neurodegenerative process, the age-related deterioration in circadian organization becomes significantly exacerbated and is responsible of behavioral problems like sundowning [176]. Age-related cognitive decline in healthy older adults can be predicted by the fragmentation of the circadian rhythm in locomotor behavior. Hence, replacement of the low melatonin levels occurring in brain [139,145] can be highly beneficial in MCI patients.

On the other hand, the bulk of information on the neuroprotective properties of melatonin derived from experimental studies (see for [177,178]) makes it highly desirable to employ pharmacological doses in MCI patients with the aim of arresting or slowing disease progression. Although the pineal gland secretes melatonin that circulates in the blood and the CSF [179], recent data support the hypothesis that, in sheep, and presumably in humans, only CSF melatonin, and not bloodstream melatonin, can provide most of melatonin to the cerebral tissue in high concentrations [180].
Significant concentration gradients oriented from the ventricle (close to the CSF) to the cerebral tissue, with concentrations varying by a factor of 1 to 125 were demonstrated. Hence, besides supporting the role of CSF in physiological availability of melatonin [179] these results imply that high, pharmacological amounts of melatonin must be given to have access to the brain.

The mechanisms accounting for the therapeutic effect of melatonin in MCI patients remain to be defined. Melatonin treatment mainly promotes slow wave sleep in the elderly [181] and can be beneficial in MCI by augmenting the restorative phases of sleep, including the augmented secretion of GH and neurotrophins.

As outlined above, melatonin acts at different levels relevant to the development and manifestation of AD. The antioxidant, mitochondrial, and antiamyloidogenic effects can possibly interfere with the onset of the disease. Therefore, the time when melatonin treatment begins can be decisive for the final response [75].

One important aspect to be considered is the melatonin dose employed, which may be unnecessarily low when one takes into consideration the binding affinities, half-life, and relative potencies of the different melatonin agonists on the market. In addition to being generally more potent than the native molecule, melatonin analogs are employed in considerably higher amounts [182]. Licensed doses of the melatonin receptor agonist ramelteon vary from 8 to 32 mg/day while agomelatine has been licensed for treatment of major depressive disorder at doses of 25–50 mg/day. In clinical studies involving healthy human subjects, tasimelteon (Vanda Pharmaceuticals, Washington, DC, USA), another melatonin receptor agonist recently approved by the FDA is administered at doses of 20 to 100 mg/day [183] while pharmacokinetics, pharmacodynamics and safety of the melatonin receptor agonist TIK-301 (Tikvah Pharmaceuticals, Atlanta, GA, USA) have been examined in a placebo controlled study using 20 to 100 mg/day [184]. Therefore, studies of MCI with melatonin doses in the range of 100–300 mg/day are further warranted.

A combination therapy of melatonin with a melatonin receptor agonist could theoretically be beneficial for AD patients, especially if the melatonin receptor agonist has a better pharmacokinetic profile than melatonin. However, melatonin receptor agonists have shown limited benefit in murine models of AD [185].

As melatonin is cleared very rapidly from the bloodstream strategies such as inhibition of melatonin degradation and clearance from the body could be a useful add-on to exogenous melatonin treatment. Indeed, pharmacological plasma levels of melatonin could be affected as a result of concurrent exposure to chemicals that modulate the expression of CYP1A2. For example, fluvoxamine, a potent inhibitor of CYP1A2 and to a lesser extent of CYP2C19, augmented plasma melatonin levels [186,187]. Likewise, the concomitant consumption of caffeine whose metabolism is principally catalyzed by CYP1A2, more than doubled plasma levels and increased the bioavailability of melatonin [188]. Another candidate is 5-methoxypsoralen, a drug used for the treatment of psoriasis, which elevates plasma levels of endogenous and exogenous melatonin [189–191].

It should be stressed that melatonin has a high safety profile, it is usually remarkably well tolerated and, in some studies, it has been administered to patients at very large doses [16,192–195]. Melatonin (300 mg/day) for up to three years decreased oxidative stress in patients with amyotrophic lateral sclerosis [192].
In children with muscular dystrophy, 70 mg/day of melatonin reduced cytokines and lipid peroxidation [193]. Doses of 80 mg melatonin hourly for 4 h were given to healthy men with no undesirable effects other than drowsiness [16]. In healthy women, given 300 mg melatonin/day for four months, there were no side effects [194]. A recent randomized controlled double-blind clinical trial on 50 patients referred for liver surgery indicated that a single preoperative enteral dose of 50 mg/kg melatonin (i.e., an equivalent to 3 g for a 60-kg adult) was safe and well tolerated [195].

Another outcome of the study recently reported [175] was that when melatonin is employed much less benzodiazepines are needed to treat sleep disturbances in MCI. Since, as above-mentioned, melatonin and benzodiazepines shared some neurochemical (i.e., interaction with GABA-mediated mechanisms in brain [196]) and behavioral properties (e.g., a similar day-dependent anxiolytic activity [46]) melatonin therapy was postulated to be an effective tool to decrease the dose of benzodiazepines needed in patients [155,197–199]. A recent retrospective analysis of a German prescriptions database identified 512 patients who had initiated treatment with prolonged release melatonin (2 mg) over a 10-month period [200]. From 112 patients in this group who had previously used benzodiazepines, 31% discontinued treatment with benzodiazepines three months after beginning prolonged release melatonin treatment. The discontinuation rate was higher in patients receiving two or three melatonin prescription [200]. The prolonged use of benzodiazepines and benzodiazepine receptor agonists (Z-drugs) is related to severe withdrawal symptoms and potential dependency, which has become a public health issue leading to multiple campaigns to decrease consumption of these drugs. A recent pharmacoepidemiological study concluded that these campaigns generally failed when they were not associated with the availability and market of melatonin [201].

5. Conclusions

In conclusion, the question as to whether melatonin has a therapeutic value in preventing or treating MCI, affecting disease initiation or progression of the neuropathology and the mechanisms involved, deserves to be further analyzed. Double-blind multicenter studies are needed to explore and investigate the potential and usefulness of melatonin as an antidementia drug at the early stage of disease.

As melatonin exhibits both hypnotic and chronobiotic properties, it has been therapeutically used for treatment of age-related insomnia as well as of other primary and secondary insomnia [202,203]. A consensus of the British Association for Psychopharmacology on evidence-based treatment of insomnia, parasomnia, and circadian rhythm sleep disorders concluded that melatonin at a dose of 2 mg is the first choice treatment when a hypnotic is indicated in patients over 55 years [204].

As shown by the binding affinities, half-life and relative potencies of the different melatonin agonists in the market it is clear that studies using these low doses of melatonin are unsuitable to give appropriate comparison with the effect of the above mentioned compounds, which in addition to being generally more potent than the native molecule are employed in considerably higher amounts [205]. Therefore, further studies employing higher melatonin doses are needed to clarify its potential therapeutical neuroprotective implications in humans. From animal studies it is clear that a number of preventive effects of melatonin, such as those in neurodegenerative disorders, need high doses of melatonin to become apparent [177]. If one expects melatonin to be an effective neuroprotector it is likely that the low doses of melatonin employed thus far are not very beneficial.
Table 2. Studies including treatment of mild cognitive impairment (MCI) patients with melatonin.

<table>
<thead>
<tr>
<th>Design</th>
<th>Subjects</th>
<th>Treatment</th>
<th>Time</th>
<th>Measured</th>
<th>Results</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Double-blind, placebo-controlled, crossover study</td>
<td>10 patients with MCI</td>
<td>6 mg melatonin p.o./daily at bed time</td>
<td>10 days</td>
<td>Actigraphy. Neuro-psychological assessment</td>
<td>Melatonin enhanced the rest-activity rhythm and improved sleep quality. The ability to remember previously learned items improved along with a significant reduction in depressed mood</td>
<td>[206]</td>
</tr>
<tr>
<td>Double-blind, placebo-controlled pilot study</td>
<td>26 patients with age-related MCI</td>
<td>1 mg melatonin p.o. or placebo at bed time</td>
<td>4 weeks</td>
<td>Sleep questionnaire and cognitive tests at baseline and at 4 weeks</td>
<td>Melatonin administration improved reported morning “restedness” and sleep latency after nocturnal awakening. It also improved scores on the California Verbal Learning Test-interference subtest.</td>
<td>[207]</td>
</tr>
<tr>
<td>Randomized, double blind, placebo-controlled study</td>
<td>354 patients with age-related MCI</td>
<td>Prolonged release melatonin (Circadin, 2 mg) or placebo, 2 h before bedtime</td>
<td>3 weeks</td>
<td>Leeds Sleep Evaluation and Pittsburgh Sleep QuestionnairesClinical Global Improvement scale score and quality of life.</td>
<td>Melatonin resulted in significant and clinically meaningful improvements in sleep quality, morning alertness, sleep onset latency and quality of life</td>
<td>[208]</td>
</tr>
<tr>
<td>Open-label, retrospective study</td>
<td>60 MCI out-patients</td>
<td>35 patients received daily 3–9 mg of a fast-release melatonin preparation p.o. at bedtime. Melatonin was given in addition to the standard medication</td>
<td>9–24 months</td>
<td>Daily logs of sleep and wake quality. Initial and final neuro-psychological assessment.</td>
<td>Abnormally high Beck Depression Inventory scores decreased in melatonin-treated patients, concomitantly with an improvement in wakefulness and sleep quality. Patients treated with melatonin showed significantly better performance in neuropsychological assessment.</td>
<td>[174]</td>
</tr>
<tr>
<td>Long-term, double-blind, placebo-controlled, 2 × 2 factorial randomized study</td>
<td>189 patients with age-related cognitive decay</td>
<td>Long-term daily treatment with whole-day bright (1000 lux) or dim (300 lux) light. Evening melatonin (2.5 mg) or placebo</td>
<td>1 to 3.5 years</td>
<td>Standardized scales for cognitive and noncognitive symptoms, limitations of activities of daily living, and adverse effects assessed every 6 months.</td>
<td>Light attenuated cognitive deterioration and ameliorated depressive symptoms. Melatonin shortened sleep onset latency and increased sleep duration but adversely affected scores for depression. The combined treatment of bright light plus melatonin showed the best effects.</td>
<td>[209]</td>
</tr>
</tbody>
</table>
Table 2. Cont.

<table>
<thead>
<tr>
<th>Study Design</th>
<th>Participants</th>
<th>Intervention</th>
<th>Duration</th>
<th>Outcome Measures</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prospective, randomized, double-blind, placebo-controlled, study</td>
<td>22 patients with age-related cognitive decay</td>
<td>Patients received 2 months of melatonin (5 mg p.o./day) and 2 months of placebo</td>
<td>2 months</td>
<td>Sleep disorders were evaluated with the Northside Hospital Sleep Medicine Institute test. Behavioral disorders were evaluated with the Yesavage Geriatric Depression Scale and Goldberg Anxiety Scale.</td>
<td>Melatonin treatment significantly improved sleep quality scores. Depression also improved significantly after melatonin administration.</td>
</tr>
<tr>
<td>Randomized double-blind, placebo-controlled study</td>
<td>25 MCI out-patients</td>
<td>11 patients received an oily emulsion of docosa-hexaenoic acid-phospho-lipids containing melatonin (10 mg) and tryptophan (190 mg)</td>
<td>12 weeks</td>
<td>Neuro-psychological assessment of orientation and cognitive functions, short-term and long-term memory, attentional abilities, executive functions, visuo-constructional and visuo-spatial abilities, language and mood.</td>
<td>Older adults with MCI had significant improvements in several measures of cognitive function when supplemented with the oily emulsion containing melatonin and tryptophan for 12 weeks, compared with the placebo. The antioxidant capacity of erythrocytes and membrane lipid composition improved after treatment.</td>
</tr>
<tr>
<td>Open-label, retrospective study</td>
<td>96 MCI out-patients</td>
<td>61 patients received daily 3–24 mg of a fast-release melatonin preparation p.o. at bedtime. Melatonin was given in addition to the standard medication</td>
<td>15–60 months</td>
<td>Daily logs of sleep and wake quality. Initial and final neuro-psychological assessment.</td>
<td>Abnormally high Beck Depression Inventory scores decreased in melatonin-treated patients, concomitantly with an improvement in wakefulness and sleep quality. Patients treated with melatonin showed significantly better performance in neuropsychological assessment. Only 6 out of 61 patients treated with melatonin needed concomitant benzodiazepine treatment vs. 22 out of 35 MCI patients not receiving melatonin.</td>
</tr>
</tbody>
</table>

[210] [211,212] [175]
Acknowledgments

Studies in the authors’ laboratories were supported by grants from the Agencia Nacional de Promoción Científica y Tecnológica, Argentina and the University of Buenos Aires. DPC is a Research Career Awardee from the Argentine Research Council (CONICET) and Professor Emeritus, University of Buenos Aires. DEV and LIB are Research Career Awardees from CONICET.

Author Contributions

DPC wrote the general outline of the review. All the other authors read and agreed on the version.

Abbreviations

Ach, acetylcholine; AChE, acetylcholinesterase; AD, Alzheimer’s disease; ADI, Alzheimer’s Disease International; AFMK, \(N^3\)-acetyl-\(N^2\)-formyl-5-methoxykynuramine; Akt, protein kinase identified in the AKT virus; AMK, \(N^3\)-acetyl-5-methoxykynuramine; APP, amyloid precursor protein; \(\text{A} \beta\), aggregated \(\beta\)-amyloid; Bcl-2, B cell lymphoma proto-oncogene protein; ChAT, choline acetyltransferase; Cox, cyclooxygenase; CSF, cerebrospinal fluid; CYP1A1, cytochrome P450 1A1; CYP1A2, cytochrome P450 1A2; CYP2C19, cytochrome P450 2C19; CYP1B1, cytochrome P450 1B1; GABA, \(\gamma\)-aminobutyric acid; GPR50, G-protein receptor 50 ortholog; GLUT-1, glucose transporter-1; GLUT-3, glucose transporter-3; GPx, glutathione peroxidase; GRd, glutathione reductase; GSH, reduced glutathione; GSK-3, glycogen synthase kinase-3; IDE, insulin-degrading enzyme; iNOS, inducible nitric oxide synthase; IGF-1, Insulin-like growth factor 1; MAP, microtubule-associated protein; MCI, mild cognitive impairment; mPTP, mitochondrial permeability transition pore; mRNA, messenger ribonucleic acid; MT1, melatonin receptor 1; MT2, melatonin receptor 2; NFkB, nuclear factor \(\kappa\)B; NMDA, \(N\)-methyl-\(D\)-aspartate; nNOS, neuronal nitric oxide synthase; NO, nitric oxide; NSAD, non-steroidal anti-inflammatory drugs; PI3-K, phosphoinositide 3-kinase; PK, protein kinase; REM, rapid eye movement; RNS, reactive nitrogen species; ROR, retinoic acid receptor-related orphan receptor; ROS, reactive oxygen species; RZR, retinoid Z receptor; SCN, suprachiasmatic nuclei; SOD, superoxide dismutase.

Conflicts of Interest

The authors declare no conflict of interest.

References

Antioxidants 2014, 3


© 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).